TY - JOUR
T1 - Differential half-maximal effects of human insulin and its analogs for in situ glucose transport and protein synthesis in rat soleus muscle
AU - Weinstein, Randi B.
AU - Eleid, Noura
AU - LeCesne, Catherine
AU - Durando, Bianca
AU - Crawford, Julie T.
AU - Heffner, Michelle
AU - Layton, Christle
AU - O’keefe, Matthew
AU - Robinson, Jennifer
AU - Rudinsky, Suzy
AU - Henriksen, Erik J.
AU - Tischler, Marc E.
N1 - Funding Information:
Supported in part by Grant No. NAG2-1187 from the National Aeronautics and Space Administration (NASA), by Novo Nordisk, Bagsvaerd, Denmark (supplier of human insulin and analogues), by the College of Science at the University of Arizona for salary support to R.B.W., and by Grant No. 71195-521304 from the Howard Hughes Medical Institute (HHMI) to the Undergraduate Biology Research Program in support of J.T.C., N.E., M.H., C. Layton, C. LeCesne, and J.R.
PY - 2002/8
Y1 - 2002/8
N2 - Analogs of human insulin have been used to discriminate between responses of metabolic and mitogenic (growth-related) pathways. This study compared the stimulatory effects of human insulin (HI) and 2 analogs (X2, B-Asp9, B-Glu27 and H2, A-His8, B-His4, B-Glu10, B-His27) on glucose uptake and protein synthesis in rat soleus muscle in situ. Glucose uptake, estimated by intramuscular (IM) injection of 2-deoxy[1, 2−3H]glucose with or without insulin, was maximally increased at 10−6 mol/L for HI and X2 and 10−7 mol/L for H2. HI had a larger effect (318%) than either X2 (156%) or H2 (124%). The half-maximal effect (ED50) values for HI, X2, and H2 were 3.3 × 10−8 mol/L, 1.7 × 10−7 mol/L, and 1.6 × 10−9 mol/L, respectively. Protein synthesis, estimated by protein incorporation of [3H]phenylalanine injected into muscles with or without insulin, was maximally increased at 10−5 mol/L for HI and 10−6 for X2 and H2. HI had a larger effect in stimulating protein synthesis (34%) than either X2 (25%) or H2 (19.8%). The ED50 values for HI, X2, and H2 were 3.0 × 10−7 mol/L, 3.2 × 10−7 mol/L, and 1.0 × 10−9 mol/L, respectively. The biological potency of each analog (ED50insulin/ED50analog) showed X2 to be less potent than HI for both glucose uptake (0.2) and protein synthesis (0.9), whereas H2 is more potent than HI with ratios of 20 and 300, respectively. These data suggest that this approach for studying insulin responsiveness in a single muscle in situ may be a useful tool for investigating insulin signaling in muscle in vivo.
AB - Analogs of human insulin have been used to discriminate between responses of metabolic and mitogenic (growth-related) pathways. This study compared the stimulatory effects of human insulin (HI) and 2 analogs (X2, B-Asp9, B-Glu27 and H2, A-His8, B-His4, B-Glu10, B-His27) on glucose uptake and protein synthesis in rat soleus muscle in situ. Glucose uptake, estimated by intramuscular (IM) injection of 2-deoxy[1, 2−3H]glucose with or without insulin, was maximally increased at 10−6 mol/L for HI and X2 and 10−7 mol/L for H2. HI had a larger effect (318%) than either X2 (156%) or H2 (124%). The half-maximal effect (ED50) values for HI, X2, and H2 were 3.3 × 10−8 mol/L, 1.7 × 10−7 mol/L, and 1.6 × 10−9 mol/L, respectively. Protein synthesis, estimated by protein incorporation of [3H]phenylalanine injected into muscles with or without insulin, was maximally increased at 10−5 mol/L for HI and 10−6 for X2 and H2. HI had a larger effect in stimulating protein synthesis (34%) than either X2 (25%) or H2 (19.8%). The ED50 values for HI, X2, and H2 were 3.0 × 10−7 mol/L, 3.2 × 10−7 mol/L, and 1.0 × 10−9 mol/L, respectively. The biological potency of each analog (ED50insulin/ED50analog) showed X2 to be less potent than HI for both glucose uptake (0.2) and protein synthesis (0.9), whereas H2 is more potent than HI with ratios of 20 and 300, respectively. These data suggest that this approach for studying insulin responsiveness in a single muscle in situ may be a useful tool for investigating insulin signaling in muscle in vivo.
UR - http://www.scopus.com/inward/record.url?scp=0036347914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036347914&partnerID=8YFLogxK
U2 - 10.1053/meta.2002.34044
DO - 10.1053/meta.2002.34044
M3 - Article
C2 - 12145783
AN - SCOPUS:0036347914
SN - 0026-0495
VL - 51
SP - 1065
EP - 1070
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 8
ER -